Results 221 to 230 of about 41,938 (307)

AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report. [PDF]

Front Oncol
Yan J, Dong H, Wu C, Gu H, Qi Z, Chen T, Hu B, Zhou H, Long J.   +8 more
europepmc   +1 more source

Socioeconomic Status and Access to Treatment in Diffuse Large B‐Cell Lymphoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Purpose Large B‐cell lymphoma (LBCL) is the most common lymphoma subtype, with diffuse LBCL (DLBCL) accounting for 30%–40% of new lymphoma cases. The International Prognostic Index (IPI) is widely used for prognostic assessment in DLBCL.
Kuitunen Joonas, Marin Katja, Tokola Susanna, Pollari Marjukka, Jyrkkiö Sirkku, Suominen Minna, Partanen Anu, Vuolukka Kristiina, Sunela Kaisa, Rönkä Aino, Aromaa‐Häyhä Annikki, Klaavuniemi Tuula, Hakalahti Anna, E. L. Kuusisto Milla, Kuitunen Hanne, Kuittinen Outi   +15 more
wiley   +1 more source

Removal of Aggregates During Bispecific Antibody Purification Using Hydrophobic Interaction Chromatography. [PDF]

Membranes (Basel)
Zhao P, Qi Y, Gao K.
europepmc   +1 more source

B‐Lymphoblastic Leukemia With Isolated Central Nervous System Relapse Mimicking a Vestibular Schwannoma

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT The central nervous system (CNS) is the most common site of extramedullary relapse in acute lymphoblastic leukemia (ALL). However, the diagnosis may be challenging due to its protean manifestations. A 64‐year‐old male reported right‐sided hearing loss with intermittent bilateral occipitotemporal headaches during a clinic follow‐up for Ph + B ...
Jun Yen Ng, Shivendra T. Lalloo, Samuel Milliken, Mark N. Polizzotto   +3 more
wiley   +1 more source

Characterization of free light chain impurity in a bispecific antibody. [PDF]

MAbs
Sadek M, Mantha N, Lippold S, Li D, Spitler K, Li R, Spinosa P, Liu B, Luu S, Woon N, Zhang Y, Guo J, Yang R, Zarzar J, Yang Y.   +14 more
europepmc   +1 more source

Molecular Structures and Molecular Interactions of Peptides and Proteins at Buried Interfaces Studied Using Sum Frequency Generation Vibrational Spectroscopy

Chemistry–Methods, Volume 6, Issue 5, May 2026.
This review provides a detailed record of recent advances in the field of determining protein conformation and orientation on various interfaces using sum frequency generation vibrational spectroscopy. We delve deep into how the addition of the Hamiltonian spectral matching formalism, isotope labeling, and Molecular Dynamics simulations has allowed us ...
Zahra Asif Gandhi, Kapil Shrawankar, Zhan Chen   +2 more
wiley   +1 more source

Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. [PDF]

Biomolecules
Seo H, Go D, Jung SY, Han S, Nguyen VQ, Kwak M, Um W.   +6 more
europepmc   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Meta-analysis of comparing CAR-T and bispecific antibody therapy in relapsed/refractory indolent B-cell non-Hodgkin's lymphomas. [PDF]

J Transl Med
Zhang MY, Cai YM, Zhu XQ, Lu KJ, Shen LJ, Du J.   +5 more
europepmc   +1 more source

In vivo CAR therapies: Turning the patient into their own CAR factory

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot, Carole‐Anne Brugère, Jaime Fuentealba, Roch Houot   +3 more
wiley   +1 more source